CAR-T cell therapeutically technology combines techniques of cell, gene, and immune therapy, which represents the cutting-edge cancer treatment. Based on the success of several clinical trials, CAR-T cell therapy has now become the most popular topic in bio-medical industry.
Acute lymphoblastic leukemia (ALL) is a malignant tumor with abnormal proliferation of B or T cells originating from lymphocytes. Abnormal proliferation of the original cells can accumulate in the bone marrow and inhibit normal hematopoiesis, and can also invade the tissues outside the marrow, such as the meninges, lymph nodes, gonadal glands, and liver. The incidence of leukemia has been investigated in China. The incidence of ALL is about 0.67/10 million. The incidence in oil fields and polluted areas is obviously higher than that in the whole country. ALL childhood (0~9 years old) is the peak of morbidity, accounting for more than 70% of childhood leukemia. ALL accounts for about 20% of adult leukemia in adults. At present, the corresponding treatment scheme based on different biological characteristics of ALL has achieved good curative effect. About 80% of children and 30% of adults can obtain long term disease free survival and have the possibility of cure.
Guangzhou Bio-gene Technology Co., Ltd (brief as Guangzhou Bio-gene) is a Chinese biotechnology company based in Guangzhou city, Guangdong Province, specializing in the discovery, development and delivery of novel cell therapies for the treatment of blood malignancies and solid tumors. Since founded in 2015, Guangzhou Bio-gene has been a fully owned subsidiary of HEDY Group Co., LTD
Attention to scanning two-dimensional code
